AbbVie's Rinvoq Demonstrates Superiority Over Humira in Rheumatoid Arthritis Study
ABBV is trading near its 52-week low of $176.57 (13% above the low).
Summary
AbbVie's Rinvoq (upadacitinib) demonstrated superiority over Humira (adalimumab) for the primary endpoint in a head-to-head rheumatoid arthritis study, achieving low disease activity and remission at week 12. The study also met the majority of ranked secondary endpoints, with no new safety risks identified for Rinvoq during the 12-week period. This is a highly significant positive development for AbbVie, as Rinvoq is a critical successor drug intended to offset revenue declines from Humira's impending biosimilar competition. The positive head-to-head data provides a strong competitive advantage, bolstering Rinvoq's market positioning and potential for increased adoption in the substantial rheumatoid arthritis market. This news reinforces the strategic importance of Rinvoq, which the company's 2025 annual report highlighted with market exclusivity extending to 2037. Traders will be watching for further clinical data, regulatory approvals in other indications, and Rinvoq's sales trajectory as it continues to gain market share.
At the time of this announcement, ABBV was trading at $199.06 on NYSE in the Life Sciences sector, with a market capitalization of approximately $349.1B. The 52-week trading range was $176.57 to $244.81. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.